Table 1. Anticancer (IC50) and hemolytic (MHC) activities of drugs against cancer cells and human red blood cells.
| Drugs | IC50a(μg/ml) | MHCb (μg/ml) | ||
|---|---|---|---|---|
| 24 h | 1.5 h | |||
| HepG2 | HeLa | HeLa | ||
| HPRP-A1 | 27.05 ± 0.13 | 25.22 ± 0.18 | 25.52 ± 0.11 | 154.7 ± 4.32 |
| HPRP-A2 | 23.56 ± 0.11 | 25.85 ± 0.23 | 23.40 ± 0.09 | 148.3 ± 5.37 |
| EPI | 1.98 ± 0.22 | 1.55 ± 0.17 | > 500 | — |
| DOX | 2.38 ± 0.15 | 2.14 ± 0.24 | > 500 | — |
__: Data not tested.
a
Anticancer activity (IC50) represents the concentration of drug at which cell viability was reduced by 50% compared with untreated cells.
b
Hemolytic activity (MHC) was determined on human red blood cells after incubating with peptides for 1.5 h.